相关实验视频

Updated: Jul 5, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

来自Scindapsus officinalis (Roxb.) 的二次代谢产物斯科特. 斯科特. 斯科特. 斯科特. 斯科特. 具有体外抗糖尿病活性

Lei Zhao¹, Yan Wang¹, Zhenqiang Wang²

¹Chemical Technology Research Institute of Shandong, Qingdao University of Science and Technology, Jinan 250014, PR China.

|January 15, 2024

概括

研究人员从Scindapsus officinalis中发现了新型化合物,其中三种通过提高胰岛素抵抗模型中的葡萄糖消耗来显示显著的抗糖尿病活性.

科学领域:

自然产品化学自然产品化学
药理学药理学是指药理学的学科.
药用化学医学化学

背景情况:

斯金达普斯 (Scindapsus officinalis) 是一种具有传统使用历史的植物.
研究其化学成分可能会揭示新的生物活性化合物.
了解其治疗效果的分子基础至关重要.

研究的目的:

从Scindapsus officinalis中分离和描述新的化学实体.
评估这些化合物的抗糖尿病和抗炎潜力.
报告第一个结合性环丁二醇和染色体糖化物的天然产品.

主要方法:

在Scindapsus officinalis.的水中提取水.
使用色谱技术分离和净化化合物.
通过HRESIMS,NMR,ECD和计算计算来阐明结构.
在体外测试使用胰岛素抵抗模型 (HepG2细胞) 检测抗糖尿病活性.
在体外测定抗炎活性测量氧化 (NO) 生产.

主要成果:

他们分离了五种化合物:一种新的性环丁醇结合的染色体糖化物 (1),一种新的胺基 (2),以及三种新的乙醇糖化物 (3-5).
化合物1代表了自然界中一种新的化学结构.
化合物1-3通过促进胰岛素抵抗性HepG2细胞的葡萄糖消耗,显示出显著的抗糖尿病活性.
化合物1-5表现出较弱的抗炎活性.

结论:

在Scindapsus officinalis中,可以产生具有潜在治疗应用的新型化合物.
化合物1-3是开发新的抗糖尿病药物的有希望的候选者.
需要进一步的研究来探索抗炎性质和作用机制.

关键词:

它具有抗炎活性,具有抗炎活性.它具有抗糖尿病活性.胰岛素耐药性胰岛素耐药性是一种烯酸循环butanantetraol乙烯酸联合染色体糖化.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...